Acrivon Therapeutics, Inc. Common Stock (ACRV) financials · $65.1M cap
Acrivon Therapeutics, Inc. Common Stock (ACRV) $65.1M cap.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Income | -$84.1M | -$89.2M | -$67.1M |
| Net Income | -$77.9M | -$80.6M | -$60.4M |
| EPS (Diluted) | $-2.02 | $-2.38 | $-2.74 |
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | $129.7M | $196.6M | $138.3M |
| Current Assets | $120.4M | $181.6M | $129.7M |
| Cash & Equivalents | $41.5M | $39.8M | $36.0M |
| Inventory | $0 | $0 | $0 |
| PP&E | $4.9M | $4.5M | $3.5M |
| Total Liabilities | $17.2M | $19.8M | $17.1M |
| Current Liabilities | $15.7M | $17.2M | $13.3M |
| Short-term Debt | $0 | $0 | $0 |
| Long-term Debt | $0 | $0 | $0 |
| Total Debt | $0 | $0 | $0 |
| Shareholders' Equity | $112.5M | $176.8M | $121.2M |
| Retained Earnings | -$274.9M | -$197.0M | -$116.4M |
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Cash Flow | -$63.7M | -$65.7M | -$42.6M |
| CapEx | $1.7M | $2.8M | $1.3M |
| Investing Cash Flow | $66.1M | -$51.8M | $50.7M |
| Financing Cash Flow | -$749.0K | $121.0M | -$1.6M |
| Dividends Paid | $0 | $0 | $0 |
| Net Change in Cash | $1.7M | $3.6M | $6.5M |
| Free Cash Flow | -$65.3M | -$68.4M | -$43.9M |
FAQ
What is ACRV P/E and revenue?
Acrivon Therapeutics, Inc. Common Stock (ACRV) $65.1M cap.
What is ACRV revenue?
Acrivon Therapeutics, Inc. Common Stock last cached revenue is $0 (FY2025).
Is ACRV profitable?
Acrivon Therapeutics, Inc. Common Stock last cached net income is -$77.9M.
What are ACRV total assets?
Acrivon Therapeutics, Inc. Common Stock last cached total assets are $129.7M.
What is ACRV free cash flow?
Acrivon Therapeutics, Inc. Common Stock last cached free cash flow is -$65.3M.
Not investment advice. Cached statements, not a live tape.